dupilumab治疗CRSwNP停药后临床纵向评估(CLEAR研究)
本研究为单中心回顾性真实世界研究,纳入46例经dupilumab治疗≥2年且疾病控制良好至优秀的成人CRSwNP患者,停药后随访至12个月。结果显示多数患者在停药后3个月内各项主要指标显著恶化,中位首次症状加重时间为7.6周,87.0%的患者在12个月内重新启用dupilumab,提示完全停药仅对少数患者可行。
要点
- 长期控制后完全停用dupilumab,多数患者早期复发。
- 停药后3个月内SNOT-22、VAS、NPS均显著恶化(p<0.001)。
- 87.0%患者12个月内重新启用dupilumab,主要因鼻部症状复发。
核心结论
- 长期疾病控制后完全停用dupilumab仅对少数患者可行,多数出现早期复发。
- dupilumab为疾病控制性而非疾病修饰或治愈性治疗,支持个体化减量而非完全停药。
研究设计与样本
- 单中心、回顾性、真实世界研究,纳入46例成人CRSwNP患者。
- 患者接受dupilumab治疗≥2年且疾病控制良好至优秀后停药,随访至12个月。
- 停药时疾病控制依据EPOS/EUFOREA对齐标准定义(双侧NPS≤2;SNOT-22<20)。
主要发现
- 中位治疗时长189.7周;停药时平均SNOT-22为10.1±6.1,NPS为0.2±0.5。
- 停药后3个月内SNOT-22升至36.4±20.0,VAS为5.0±2.7,NPS为1.5±1.9,均p<0.001。
- 中位首次症状加重时间为7.6周。
- 87.0%的患者在12个月内重新启用dupilumab,主要因鼻部症状复发。
- 重新治疗带来快速且显著的临床改善;6例未重启治疗者呈现进行性客观和/或主观恶化。
关键数值与推荐
- 停药时疾病控制标准:双侧NPS≤2且SNOT-22<20(EPOS/EUFOREA对齐标准)。
- 纳入标准:成人CRSwNP,dupilumab治疗≥2年,持续良好至优秀疾病控制后停药。
临床怎么用
- 对长期控制良好的重度Type 2驱动CRSwNP患者,优先考虑个体化剂量递减而非完全停用dupilumab。
- 停药后应密切监测,尤其在前3个月内,因中位症状加重时间约7.6周。
局限性
- 单中心、回顾性、真实世界设计。
- 样本量较小(46例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Long-term management strategies for severe chronic rhinosinusitis with nasal polyps (CRSwNP) increasingly include biologic therapy targeting Type 2 inflammation. However, data on outcomes after complete discontinuation of dupilumab following sustained disease control are scarce. METHODS: In this single-center, retrospective real-world study, adult CRSwNP patients who discontinued dupilumab after ≥ 2 years of treatment and sustained good-to-excellent disease control were included. Disease control at cessation was defined according to EPOS/EUFOREA-aligned criteria (bilateral nasal polyp score [NPS] ≤ 2; SNOT-22 < 20). Patients were followed for up to 12 months. Outcomes included SNOT-22, visual analog scale (VAS), NPS, olfactory function (SSIT-12), relapse timing, and reinitiation of therapy. RESULTS: A total of 46 patients were included (median treatment duration 189.7 weeks). At discontinuation, disease control was excellent (mean SNOT-22 10.1 ± 6.1; NPS 0.2 ± 0.5). Within 3 months, a marked and statistically significant deterioration occurred across all major outcomes (SNOT-22 36.4 ± 20.0; VAS 5.0 ± 2.7; NPS 1.5 ± 1.9; all p < 0.001). Median time to first symptom worsening was 7.6 weeks. Most The majority of patients (87.0%) reinitiated dupilumab within 12 months, primarily due to nasal symptom recurrence. Retreatment led to rapid and significant clinical improvement. Six patients remained off therapy, but demonstrated progressive objective and/or subjective worsening over time. CONCLUSIONS: Complete discontinuation of dupilumab after long-term disease control appears feasible in only a minority of patients and is associated with early relapse in most cases. These findings support the concept of dupilumab as a disease-controlling rather than disease-modifying or curative therapy and favor individualized dose tapering over full cessation in severe Type 2-driven CRSwNP.
引用
- Huber P, Lasch M, Volgger V, et al. Clinical Longitudinal Evaluation After Regimen Stop (CLEAR) of Dupilumab in Chronic Rhinosinusitis With Nasal Polyps (CRSwNP). Int Forum Allergy Rhinol. 2026. PMID: 42579396. doi:10.1002/alr.70241
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。